Peptide vaccine-treated, long-term surviving cancer patients harbor self-renewing tumor-specific CD8+ T cells

Eishiro Mizukoshi (), Hidetoshi Nakagawa, Toshikatsu Tamai, Masaaki Kitahara, Kazumi Fushimi, Kouki Nio, Takeshi Terashima, Noriho Iida, Kuniaki Arai, Tatsuya Yamashita, Taro Yamashita, Yoshio Sakai, Masao Honda and Shuichi Kaneko
Additional contact information
Eishiro Mizukoshi: Kanazawa University
Hidetoshi Nakagawa: Kanazawa University
Toshikatsu Tamai: Kanazawa University
Masaaki Kitahara: Kanazawa University
Kazumi Fushimi: Kanazawa University
Kouki Nio: Kanazawa University
Takeshi Terashima: Kanazawa University
Noriho Iida: Kanazawa University
Kuniaki Arai: Kanazawa University
Tatsuya Yamashita: Kanazawa University
Taro Yamashita: Kanazawa University
Yoshio Sakai: Kanazawa University
Masao Honda: Kanazawa University
Shuichi Kaneko: Kanazawa University

Nature Communications, 2022, vol. 13, issue 1, 1-11

Abstract: Abstract The behaviors and fates of immune cells in cancer patients, such as dysfunction and stem-like states leading to memory formation in T cells, are in intense focus of investigation. Here we show, by post hoc analysis of peripheral blood lymphocytes of hepatocellular carcinoma patients previously undergoing vaccination with tumour-associated antigen-derived peptides in our clinical trials (registration numbers UMIN000003511, UMIN000004540, UMIN000005677, UMIN000003514 and UMIN000005678), that induced peptide-specific T cell responses may persist beyond 10 years following vaccination. Tracking TCR clonotypes at the single cell level reveals in two patients that peptide-specific long-lasting CD8+ T cells acquire an effector memory phenotype that associates with cell cycle-related genes (CCNA2 and CDK1), and are characterized by high expression of IL7R, SELL, and NOSIP along with a later stage promotion of the AP-1 transcription factor network (5 years or more past vaccination). We conclude that effective anti-tumor immunity is governed by potentially proliferative memory T cells, specific to cancer antigens.

Date: 2022
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-022-30861-z Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-022-30861-z

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-022-30861-z

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().